Navigation Links
Why 'event cloaks' could be the key to the ultimate bank heist
Date:6/30/2011

In this month's special issue of Physics World, which examines the science and applications of invisibility, Martin McCall and Paul Kinsler of Imperial College London describe a new type of invisibility cloak that does not just hide objects but events.

Using the ultimate bank heist as an example, McCall and Kinsler explain how a thief could, in principle, use an "event cloak" to steal money from a safe, without even the CCTV surveillance cameras being aware.

The burglar would somehow need to split all the light approaching the safe into two parts: "before" and "after", with the "before" part sped up and the "after" part slowed down.

This would create a brief period of darkness during which the burglar could enter the scene and steal the money, being careful to close the safe door before they leave.

With the safe-cracker gone, the process of speeding up and slowing down the light would then be reversed, leading to an apparently untouched scene once again.

Robbing a bank is, of course, only an example to illustrate the principle of what an event cloak could do. As McCall and Kinsler explain, a more likely application of a full-size event cloak would be to control the flow of signals in an optical routing system, where one may need to process simultaneous uninterrupted signals at the same time.

For these aspirations to become a reality, suitable materials need to be developed that can manipulate the light to speed it up or slow it down. The consensus seems to be that a set of parallel, artificially structured "metamaterial" layers would be needed, each containing an array of tiny metallic elements that can be controlled to dynamically adjust the speed of light passing through.

If a high-performance, macroscopic-size, fully functional spacetime cloak could be developed, one potential "party trick" could be a Star Trek-type transporter, in which a person could appear to instantly relocate from one point to another.

Although no-one has yet tried to build a spacetime cloak in the lab, McCall and Kinsler argue that "there is no obvious reason why such a cloak could not be achieved quite soon, perhaps even within a few years".

Also in this month's special issue on invisibility.

  • Invisibility is now a reality, but scientists are not satisfied and are still searching for the holy grail a cloak of invisibility that can hide macroscale objects from view at any angle, using unpolarized visible light. Wenshan Cai and Vladimir Shalaev map out the road ahead on this mission.

  • The quest to achieve true invisibility has inspired ambitious goals beyond merely cloaking visible light. Ulf Leonhardt takes a light-hearted look at the top five possible spin-offs from invisibility science.

  • Tales of invisible people and magical invisibility-bestowing objects have thrilled us for millennia. Sidney Perkowitz reveals how these myths and fantasies are now becoming a reality.


'/>"/>

Contact: Michael Bishop
michael.bishop@iop.org
44-117-930-1032
Institute of Physics
Source:Eurekalert

Related biology technology :

1. Amgen Submits Application to Expand Indication for XGEVA® (Denosumab) to Prevent or Delay Spread of Prostate Cancer to the Bone
2. New Jersey Targets Life-Sciences Investors at Worlds Largest Biotechnology Event
3. Verizon to Invest $125,000 to Support Domestic Violence Outreach, Prevention, Education and Awareness Programs in Virginia
4. NeoStem to Present at Two Investor Events This Month
5. Researchers From More Than 30 Countries Share Findings About the Use of Ultrasound in the Prevention, Diagnosis and Treatment of Heart Disease
6. Hospital for Special Surgery to Host International Arthritis Summit: Frontiers in Osteoarthritis Research, Prevention and Care
7. LifeVantages Nrf2 Activator Reviewed for Tumor Prevention and Suppression in New Peer-Reviewed Article
8. Advantagene Announces SPA Agreement With FDA to Launch Phase 3 Trial for Novel Vaccine Aimed at Preventing Prostate Cancer Recurrence
9. Phase 3 Data Demonstrate XGEVA™ (Denosumab) is First Bone Targeted Therapy to Prevent Spread of Cancer to the Bone in Men With Advanced Prostate Cancer
10. MiMedx Group, Inc. to Present at the Noble Financial Capital Markets Seventh Annual Equity Conference
11. PharmacoFore, Inc. Announces Sponsorship of the 2011 CLAAD National Prescription Drug Abuse Prevention Policy Consensus Meeting on November 29, 2011 in Washington, DC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... ... May 25, 2017 , ... Throughout this webinar, participants will ... process development and economic goals were achieved in both industry and academic settings. ... system, along with techniques for scaling production of mesenchymal stem cells (MSCs) and ...
(Date:5/24/2017)... BOUNTIFUL, Utah (PRWEB) , ... May 24, 2017 ... ... announces the selection and implementation of CLEARAS Water Recovery’s Advanced Biological Nutrient Recovery ... a key component of a $24 million plant upgrade to sustainably meet current ...
(Date:5/24/2017)... May 23, 2017 As Ebola resurfaces in the ... deaths and 20 suspected cases now reported, a new analysis ... database, showed a correlation between the 2014 and 2017 outbreaks ... rose sharply in 2012-13, which preceded the 2014 outbreak. An ... Ebola gene Replikin counts in 2014-15, which again precedes the ...
(Date:5/23/2017)... ... May 23, 2017 , ... Genedata, a ... anniversary, marking the occasion with a strong presence at Bio-IT World Conference & ... further extends an invitation to all attendees to view posters on the ...
Breaking Biology Technology:
(Date:4/5/2017)... 2017  The Allen Institute for Cell Science today ... one-of-a-kind portal and dynamic digital window into the human ... first application of deep learning to create predictive models ... and a growing suite of powerful tools. The Allen ... future publicly available resources created and shared by the ...
(Date:4/3/2017)... April 3, 2017  Data captured by ... platform, detected a statistically significant association between ... to treatment and objective response of cancer ... to predict whether cancer patients will respond ... as well as to improve both pre-infusion potency ...
(Date:3/29/2017)... 2017  higi, the health IT company that operates ... America , today announced a Series B investment ... EveryMove. The new investment and acquisition accelerates higi,s strategy ... transform population health activities through the collection and workflow ... higi collects and secures data today on behalf of ...
Breaking Biology News(10 mins):